Table 5.
Human predicted survival probability at key study time points using a NHP dual correlate peak and last model.
| Peak anti-PA IgG, last anti-PA
IgG |
Peak ED50, last anti-PA
IgG |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4-IM |
5-IM | 7-IM | 4-IM |
5-IM |
7-IM |
||||||||
| Time point (months) | NHP N | Human N | % Survival (95% CI) | Human N | % Survival (95% CI) | Human N | % Survival (95% CI) | Human N | % Survival (95% CI) | Human N | % Survival (95% CI) | Human N | % Survival (95% CI) |
| 7 | 137 | 220 | 99.1 (95.4–99.9) | 202 | 99.0 (95.0–99.8) | 214 | 99.3 (95.9–99.9) | 99 | 98.7 (94.5–99.9) | 88 | 99.2 (95.0–99.9) | 102 | 99.2 (95.4–99.9) |
| 12 | 137 | 210 | 96.3 (91.2–98.8) | 192 | 96.2 (90.9–98.7) | 206 | 96.8§ (91.7–99.1) | 94 | 95.4 (88.7–98.7) | 82 | 96.6 (90.4–99.2) | 98 | 96.4§ (90.2–99.1) |
| 13 | 137 | 206 | 95.7* (90.7–98.3) | 184 | 95.6* (90.1–98.7) | 198 | 99.4(96.4–100.0) | 90 | 95.2* (88.7–98.5) | 79 | 95.8* (89.4–98.8) | 94 | 99.4(95.5–100.0) |
| 18 | 137 | 197 | 93.0* (87.5–96.7) | 175 | 92.8§,* (87.2–96.8) | 189 | 97.8§ (93.2–99.6) | 85 | 92.2* (85.7–96.6) | 73 | 93.4§,* (86.9–97.4) | 89 | 97.5§ (91.7–99.5) |
| 19 | 137 | 189 | 93.0*,† (87.8–96.7) | 170 | 99.5 (96.6–100.0) | 187 | 99.4 (96.4–99.9) | 81 | 92.3*,† (85.4–96.8) | 70 | 99.5 96.2–100.0) | 87 | 99.4 (95.6–100.0) |
| 30 | 137 | 178 | 89.8*,† (84.5–94.4) | 159 | 96.5 (91.4–98.8) | 175 | 96.7§ (91.7–99.1) | 76 | 89.0*,† (82.2–94.5) | 65 | 96.4 (90.5–99.1) | 82 | 96.4§ (90.4–99.1) |
| 31 | 137 | 175 | 89.4*,† (83.6–94.3) | 150 | 96.4* (91.4–98.9) | 166 | 99.5 (97.0–100.0) | 74 | 87.7*,† (81.7–93.6) | 62 | 96.5* (91.0–99.3) | 76 | 99.5 (96.3–100.0) |
| 42 | 137 | 158 | 87.1§,*,† (81.1–92.5) | 142 | 95.2§,* (89.9–98.3) | 143 | 97.5§ (92.8–99.5) | 68 | 85.1§,*,† (78.0–91.5) | 58 | 95.7§ (89.4–98.9) | 64 | 97.4§ (91.1–99.5) |
| 43 | 137 | 154 | 99.5 (96.8–100.0) | 138 | 99.5 (96.6–100.0) | 135 | 99.5 (97.0–100.0) | 64 | 99.5 (96.2–100.0) | 55 | 99.5 (96.0–100.0) | 58 | 99.5 (96.2–100.0) |
Predicted % survival in human cohorts based on the NHP dual-correlate models (peak anti-PA IgG and last anti-PA IgG, or peak ED50 and last anti-PA IgG). All 137 NHP were used for the model. Confidence intervals (95% CI) are in parentheses.
§
Time points where boosters were administered.
*
Statistically significant difference from the 7-IM group.
†
Statistically significant difference from the 5-IM group.